Cytek Biosciences Stock (CTKB) Opinions on Preliminary Q4 and FY2025 Revenue Results

Revenue Surge Ignites Chatter: Cytek Biosciences shares advanced sharply on social media radars following the disclosure of preliminary fourth-quarter and full-year 2025 revenue figures. The results underscored substantial growth across diverse regions and segments, drawing attention from traders scanning for momentum plays.

Bullish Momentum Builds: Conversations highlight the company's expanding footprint as a key driver, with users noting the positive trading reaction. Amid listings with other volatile names, the overall tone reflects optimism for sustained performance.

Eyes on Next Catalysts: Investors on social media are positioning the revenue beat as a pivotal moment, speculating on broader market implications for biotech innovators like Cytek.

Note: This discussion summary was generated from an AI condensation of post data.

Cytek Biosciences Revenue

Cytek Biosciences had revenues of $52.3M in Q3 2025. This is an increase of 1.54% from the same period in the prior year.

You can track CTKB financials on Quiver Quantitative's CTKB stock page.

Cytek Biosciences Hedge Fund Activity

We have seen 77 institutional investors add shares of Cytek Biosciences stock to their portfolio, and 83 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 2,541,046 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,817,429
MILLENNIUM MANAGEMENT LLC added 2,493,610 shares (+269.6%) to their portfolio in Q3 2025, for an estimated $8,652,826
BROWN CAPITAL MANAGEMENT LLC removed 2,151,979 shares (-30.3%) from their portfolio in Q3 2025, for an estimated $7,467,367
NEW YORK STATE COMMON RETIREMENT FUND removed 1,757,200 shares (-84.1%) from their portfolio in Q3 2025, for an estimated $6,097,484
TOPLINE CAPITAL MANAGEMENT, LLC added 1,713,020 shares (+32.7%) to their portfolio in Q3 2025, for an estimated $5,944,179
VANGUARD GROUP INC added 541,973 shares (+7.8%) to their portfolio in Q4 2025, for an estimated $2,736,963
CITADEL ADVISORS LLC removed 534,781 shares (-86.7%) from their portfolio in Q3 2025, for an estimated $1,855,690

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Cytek Biosciences Government Contracts

We have seen $1,026,135 of award payments to $CTKB over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Cytek Biosciences Analyst Ratings

Wall Street analysts have issued reports on $CTKB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

TD Cowen issued a "Buy" rating on 01/08/2026
Piper Sandler issued a "Overweight" rating on 11/11/2025

To track analyst ratings and price targets for Cytek Biosciences, check out Quiver Quantitative's $CTKB forecast page.

Cytek Biosciences Price Targets

Multiple analysts have issued price targets for $CTKB recently. We have seen 2 analysts offer price targets for $CTKB in the last 6 months, with a median target of $6.25.

Here are some recent targets:

Brendan Smith from TD Cowen set a target price of $5.0 on 01/08/2026
David Westenberg from Piper Sandler set a target price of $7.5 on 11/11/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.